SCHEMBL479078

SCHEMBL479078

CN(c1ccc(CP(=O)(O)O)cc1)c1cnc2nc(N)nc(N)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46
DHFR P00374 16/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
KDM4E B2RXH2 1/20 0.39
TLR4 O00206 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
TYMS P04818 1/20 0.39
GLA P06280 1/20 0.39
POLB P06746 1/20 0.39
HMGB1 P09429 1/20 0.39
MAPT P10636 1/20 0.39
FOLR2 P14207 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13584032 0.87 DHFR (0.43) HDAC4HDAC7HDAC9HDAC5DHFR
SCHEMBL479287 0.85 HDAC4 (0.48) HDAC4HDAC7HDAC9HDAC5DHFR
SCHEMBL479157 0.83 DHFR (0.45) DHFRCA1CA2CA9KDM4E
SCHEMBL479227 0.79 DHFR (0.40) HDAC4HDAC7HDAC9HDAC5DHFR
SCHEMBL479241 0.78 DHFR (0.41) HDAC4HDAC7HDAC9HDAC5DHFR
Water SCHEMBL9320891 0.78 DHFR (0.49) HDAC4HDAC7HDAC9HDAC5DHFR
SCHEMBL13583145 0.78 CA1 (0.55) DHFRCA1CA2CA9
SCHEMBL479058 0.78 DHFR (0.41) HDAC4HDAC7HDAC9HDAC5DHFR
Butane SCHEMBL479225 0.77 DHFR (0.41) DHFRCA1CA2CA9
SCHEMBL479348 0.77 DHFR (0.45) HDAC4HDAC7HDAC9HDAC5DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283219-A1 DIAMINOPTERIDINE DERIVATIVES BIORELIX, INC. 2012-11-08 US disclosed
EP-2410856-A1 DIAMINOPTERIDINE DERIVATIVES Biorelix, Inc. (US) 2012-02-01 EP disclosed
WO-2010110907-A1 DIAMINOPTERIDINE DERIVATIVES BIORELIX, INC. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283219-A1 DIAMINOPTERIDINE DERIVATIVES MPO, AOC1, DCTD HDAC4 2319/4885HDAC7 1983/4885HDAC9 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.